BioVie Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
BioVie Inc. (BIVI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.50 thousand shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was -154.71K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 105.00K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-09-30 was 100.00 shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-06-30 was 100.00 shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2026 was 1.50K shares, a 91.27% decline from fiscal 2025.
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 17.19K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 68.71K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 1.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 1.50K shares 10-K · filed 2026-08-13 | ||||
| 2025-06-30 | -154.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-13 | -49.71K shares derived: sum of 2 quarters · filed 2026-08-13 | 17.19K shares 10-K · filed 2026-08-13 | ||
| 2025-03-31 | 105.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | 171.90K shares 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | 66.90K shares 10-Q · filed 2025-02-11 | ||||
| 2024-06-30 | 10.41K shares S-1/A · filed 2026-08-06 | ||||
| 2023-06-30 | 68.71K shares 10-K · filed 2024-09-30 | ||||
| 2017-09-30 | 100.00 shares 10-Q · filed 2017-11-08 | 200.00 shares derived: sum of 2 quarters · filed 2017-11-08 | 300.00 shares derived: sum of 3 quarters · filed 2017-11-08 | 1.10K shares derived: sum of 4 quarters · filed 2017-11-08 | |
| 2017-06-30 | 100.00 shares derived: 10-K 12 month − 3 quarters · filed 2017-08-24 | 200.00 shares derived: sum of 2 quarters · filed 2017-08-24 | 1.00K shares derived: sum of 3 quarters · filed 2017-08-24 | 1.00K shares 10-K · filed 2017-08-24 | |
| 2017-03-31 | 100.00 shares 10-Q · filed 2017-05-09 | 900.00 shares derived: sum of 2 quarters · filed 2017-05-09 | 900.00 shares derived: sum of 3 quarters · filed 2017-05-09 | ||
| 2016-12-31 | 800.00 shares 10-Q · filed 2017-05-09 | 800.00 shares derived: sum of 2 quarters · filed 2017-05-09 | |||
| 2016-09-30 | 0.00 shares 10-Q/A · filed 2017-01-19 | ||||
| 2016-06-30 | 1.00K shares 10-Q · filed 2017-11-08 | 3.00K shares 10-Q · filed 2016-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |